We develop neuroimaging and genetic solutions for the early detection and prediction of Alzheimer’s disease.
Neurozen is dedicated to developing advanced, deep learning-enabled neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease.
Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or cognitive decline has occurred.
Our mission is to provide innovative, quality clinical tools to predict, quantify, and monitor neurodegeneration so that physicians can be more confident in making important clinical decisions and people can enjoy a higher quality of life.
Neurozen has an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD).
This cohort is an ongoing, longitudinal, multicenter study collecting clinical, neuropsychological, imaging (MRI and PET) and genomic data.
We work with a diverse network of neuroscientists, radiologists, bioinformatics specialists, and dementia experts to develop unique and effective solutions for Alzheimer's disease.
Using deep learning technology, we have developed a normative database to empower accurate comparisons and more informed diagnoses.
Korean genomics-based prediction of
High risk individual of Alzheimer’s disease
KCDC genetic test approved
Service launch in June 2022
Digitalized visuospatial cognitive test
AI-based automatic evaluation
Beta version launch in July 2022
Service launch in October 2022
MRI and APOE genotype-based
Amyloid PET positivity prediction
In clinical trial (KFDA medical device level 3)
Expect to be approved in 2022
Professor at Chosun University (current)
Director of the National Research Center for Dementia and the GARD Cohort Research Center (current)
Seoul National University, PhD in Molecular Biology
Get product and service updates, important events, and promotions straight to your inbox.